

Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Symproic (naldemedine) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 6 months; Continuation- 12 months

## **Instructions:**

This form is used by Kaiser Permanente and/or participating providers for coverage of **Symproic (naldemedine).**Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.** 

KP-MAS Formulary can be found at: <a href="Pharmacy">Pharmacy</a> | Community Provider Portal | Kaiser Permanente</a>

	1 – Patient Information	
Patient Name:	Kaiser Medical ID#:	Date of Birth:
	2 – Prescriber Information	
Prescriber Name:	Specialty:	NPI:
Prescriber Address:		
Prescriber Phone #:	Prescriber Fax #:	
	3 – Pharmacy Information	
Pharmacy Name:	Pharmacy NPI:	
Pharmacy Phone #	Pharmacy Fax #:	
	4 – Drug Therapy Requested	
J.8		
Sig:		
	5- Diagnosis/Clinical Criteria	
<ol> <li>Is this request for initial or cont</li> <li>Initial therapy</li> </ol>	inuing therapy?   — Continuing therapy, state start date:	
	for the requested medication:	
Clinical Criteria:  1. Prescriber is a Gastroenterologi	st. Oncologist, or Pain Specialist.	

	□ No □ Yes
2.	<b>ND</b> member has a diagnosis of opioid induced constipation in an adult with an active opioid prescription $\Box$ No $\Box$ Yes
3.	ND opioid medication is being prescribed by an oncologist or a hospice/palliative care clinician for a member urrently enrolled in hospice or palliative care program, or after consultation with a pain management pecialist  □ No □ Yes
4.	ND member has failed a trial of at least 2 weeks or has an intolerance or contraindication to scheduled dosing of the following medications, used in combination with other agent(s) with different mechanism of action (i.e., osmot with a stimulant) and route of administration:  Polyethylene glycol Lactulose or sorbitol Senna Bisacodyl  No  Yes
5.	ND member has inadequate response, contraindication or intolerance to both of the following:  Generic Amitiza (lubiprostone) − 1 <sup>st</sup> line  Movantik − 2 <sup>nd</sup> line  □ No □ Yes
For cor 1.	nuation of therapy, please respond to <u>additional question</u> below:  Iember has a positive clinical response to Symproic  □ No □ Yes
	6 – Prescriber Sign-Off
Additio	al Information –
2. <b>If</b>	se submit chart notes/medical records for the patient that are applicable to this request.  ember has not tried preferred agent(s) please provide rationale/explanation and any additional supporting  mation that should be taken into consideration for the requested medication:
Logrt	that the information provided is accurate. Supporting documentation is available for State audits.
	ber Signature:  Date:
infori	ote: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The ion is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, ion or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not

intended for receipt by your facility